



**Interim Report**  
**January - March 2026**

## Acarix First Quarter 2026 Summary

### KEY Q1 TAKEAWAYS

#### First quarter 2026 compared to the same period in 2025

- Total revenue amounted to SEK 2,424 thousand (1,729), an increase of 40%
- In the U.S., revenue amounted to SEK 2,010 thousand (1,234) and an increase by 63%
- Currency adjusted revenue increased by totally 61% and in US by 90%
- A total of 29 CADScor Systems (19) were delivered in the U.S market, an increase of 53%.
- A total of 172 boxes of patches (158) were sold, reflecting a 9% increase.
- In the U.S. patch sales amounted to 122 boxes (106), an increase of 15%
- Gross margin amounted to 81% (81%)
- Operating costs amounted to SEK 10,421 thousand (15,437), a decrease of 32%
- Net loss was SEK -8,781 thousand (-14,108), an improvement of 38%
- Cash flow from operating activities was SEK 1,113 thousand (-11,667)
- Earnings per share were SEK -0.01 (-0.01)

#### Significant Events during the Quarter

- Acarix announced that the CADScor System successfully achieved certification under the European Union Medical Device Regulation (EU MDR 2017/745). The MDR certification confirms that the CADScor System meets the European Union's most stringent regulatory requirements for safety, quality, and clinical performance.
- Acarix announced that it has entered into a strategic distribution partnership with a new partner in the Kingdom of Saudi Arabia. Following successful regulatory approval which is supported by the recently announced MDR approval, the partner has forecasted product orders totaling approximately SEK 9,8 million within the first 6 months after approval.

#### Significant events after the quarter

- Acarix announced the presentation of its abstract titled "A Novel Point-of-Care Device Comparing Diagnostic Utility to Standard Stress Tests in Chest Pain Patients" at the American College of Cardiology's 75th Annual Scientific Session & Expo (ACC.26). The data demonstrates a high negative predictive value (NPV) for the CADScor® System and indicates substantial operational benefits versus conventional stress testing pathways, including potential care time savings of up to 40 hours and cost reductions exceeding \$100,000 per inpatient case and \$4,000 per outpatient case.

## Comments from the CEO

The first quarter of 2026 marks a strong and encouraging start to the year for Acarix, reflecting continued progress across our key strategic priorities and growing momentum in our core U.S. market. Throughout the quarter, we remained focused on expanding adoption of the CADScor® System while continuing to build a more efficient and financially disciplined organization. Revenue increased by 40% year-over-year and, adjusted for currency effects, revenue growth reached 61% overall, including 90% growth in the U.S. At the same time, we significantly improved our cost base, reducing operating expenses by 32% and improving net loss by 38% compared to the same period last year. Together, these results demonstrate the progress we are making in balancing commercial execution with disciplined operational management.

Our U.S. market remains the primary engine of growth. During the quarter, we delivered 29 CADScor® Systems, representing a 53% increase compared to the same period last year. We continue to see encouraging engagement across our installed base as clinicians increasingly incorporate the CADScor® System into frontline cardiac assessment workflows. Expanding system placements remains a key driver of our long-term strategy, creating a broader foundation for recurring revenue and supporting the scalability of our commercial model over time.

In addition, we are seeing continued validation of our commercial approach through growing interest from healthcare providers and partners across both existing and new markets. As more clinicians integrate the CADScor® System into routine practice, we are strengthening our position within frontline cardiac diagnostics while continuing to build awareness of the clinical value our technology can deliver in everyday care settings.

During the quarter, we achieved MDR certification in the European Union, an important regulatory milestone that validates the safety and performance of the CADScor® System. This certification supports our continued presence in Europe and provides a strong foundation for future international expansion. In parallel, we expanded our geographic footprint through a new distribution partnership in Saudi Arabia, highlighting the effectiveness of our partner-led expansion strategy. While ongoing geopolitical tensions in the Middle East may impact the pace of progress in certain markets, we continue to see meaningful opportunities in the region and remain confident in the long-term potential of our expansion efforts. More broadly, we are also engaged in discussions with potential partners in additional new markets, reflecting growing international interest in the CADScor® System and our non-invasive approach to frontline cardiac diagnostics.

Entering the remainder of 2026, our priorities are centered on converting system placements into broader clinical adoption, continuing progress under the Rural Health Transformation Program (RHTP), further strengthening our reimbursement foundation in the U.S., and expanding access to the CADScor® System across both existing and new markets. As adoption continues to grow and clinicians increasingly integrate the CADScor® System into routine patient pathways, we believe we are well positioned to strengthen our role in frontline cardiac diagnostics.

We are encouraged by the progress in the first quarter and believe Acarix is well positioned to build on this momentum throughout 2026, continuing to expand access to early, non-invasive cardiac diagnostics while creating long-term value for patients, providers, and shareholders.

**Aamir Mahmood**  
President & CEO

## Financial Reports

### Profit/Loss Statements

#### First quarter

The Group reported total revenue of SEK 2,424 thousand for the first quarter of 2026, representing a 40 percent increase compared to SEK 1,729 thousand in the same period of the previous year. Revenue generated in the U.S. market amounted to SEK 2,010 thousand, an increase of 63 percent from SEK 1,234 thousand in the corresponding quarter of the prior year. Excluding currency effects, total revenue increased by 61 percent, while U.S. revenue, adjusted for currency effects, grew by 90 percent.

During the quarter, a total of 29 CADScor Systems were delivered, including 25 units sold and 4 units on consignment, all within the U.S. market. This represents a 53% increase in the US compared to the previous period's 19 units. Patch sales totaled 172 boxes, marking a 9% rise from 158 boxes. In the U.S., patch sales reached 122 boxes, an increase of 15% from 106 boxes. The gross margin remained steady at 81%, consistent with the prior period.

Operating costs totaled SEK 10,421 thousand, representing a reduction of 32% from SEK 15,437 thousand in the previous period. The company remains committed to improving cost efficiency by optimizing operational processes and reducing expenses, with the goal of supporting sustainable growth and enhancing overall operating results.

Net loss for the quarter amounted to SEK –8,781 thousand, compared to SEK –14,108 thousand in the previous period. This represents an improvement of 38%, reflecting the company's ongoing efforts to enhance financial performance.

### Financial Position Overview

Tangible assets amounted to SEK 192 thousand, primarily related to the net value of CADScor Systems under the consignment model in the U.S. market. Intangible assets, which include the net value of patents and development costs, totaled SEK 5,854 thousand, a decrease from SEK 8,456 thousand as of March 2025. No acquisitions were made during the period.

Inventory value was SEK 6,253 thousand, reflecting a 2% decline from SEK 6,404 thousand at March 2025. The company's cash balance was SEK 25,793 thousand, compared to SEK 45,048 thousand in March 2025.

As of March 31, the company's equity stood at SEK 36,956 thousand, down from SEK 59,909 thousand as of March 2025. The share capital was SEK 11,875 thousand, with a total of 1,187,498,248 shares registered with the Swedish Companies Registration Office.

Total current liabilities increased to SEK 6,548 thousand from SEK 4,830 thousand in the first quarter previous year.

### Cash Flow and Financing

#### First quarter

Cash flow from operating activities, including changes in working capital, totaled SEK 1,113 thousand (SEK -11,667 thousand) for the period. The positive cash flow primarily reflects the positive change in working capital amounting SEK 9,241 thousand (SEK 1,550 thousand). Under the item Changes in receivables and prepayments SEK 11,793 thousand was included as a receivable from the share issuance bank, which as of December 2025 was holding liquid funds for registered shares in the ongoing issue. The payment was made to the company during January 2026.

Under the item Changes in trade and other liabilities SEK 2,820 thousand is included, representing a paid-up share issue amount that has not yet been registered with the Swedish Companies Registration Office as of March 2026. Cash flow from financing activities includes the ongoing directed issue amounting to SEK 5,884 thousand, including transaction costs. The net cash flow for the period was SEK 7,177 thousand (SEK -11,767 thousand).

### **Financing**

At the beginning of the fourth quarter 2025, the Board approved a directed share issue targeting U.S. and Nordic investors, expected to raise approximately SEK 33.4 million gross before issuance costs. By March 31, 2026, SEK 21.1 million had been received into the company's share issue account. The share issuance is ongoing, with full payment expected to be completed within the first six months of 2026.

The Board of Directors and executive management work continuously to secure the company's long-term financing to ensure the operation of the business. The company's growth plan is continuously balanced against the financial resources available at any given time. The established growth plan, which is driven by market demand, may require additional financing later in the fourth quarter of 2026, which could be obtained through, for example, loans or share issuance.

### **The Parent Company**

The Parent Company is primarily responsible for the financial management of the Group. The company reported a net loss of SEK -6.445 (-15,712) thousand, primarily due to a SEK -6,024 (-16,628) thousand write-down and expense of shareholder contributions to subsidiaries, which are reflected as a financial item in the parent company's income statement. As of March 31, shares in subsidiaries amounted to SEK 44,592 thousand (44,868). The Parent Company's cash and cash equivalents at March 31 were SEK 21,690 thousand, compared to SEK 30,698 thousand in March 31 previous year.

### **Auditor's Review**

This Interim Report has not been reviewed by the company's auditor.

### **Certified Advisor**

The Company's Certified Adviser is Tapper Partners AB

## Shareholder Register March 31, 2026

	Number of shares	Votes and capital
Ibkr Financial Services AG	208,390,572	17.5%
Försäkringsaktiebolaget Avanza Pension	73,787,221	6.2%
Life Science Invest Fund 1 Aps	38,677,762	3.3%
Cbny-Charles Schwab Fbo Customer	35,738,814	3.0%
Carl Johan Mikael Thoren	34,097,308	2.9%
Ubp Client 211/0505602	27,731,390	2.3%
Filip Fröjden	26,367,752	2.2%
Saxo Bank A/s - Danish Client Asset	24,879,856	2.1%
Microtech Software AS	20,513,884	1.7%
Morgan Stanley Smith Barney LLC	18,789,263	1.6%
<b>10 largest owners</b>	<b>508,973,822</b>	<b>42.9%</b>
<b>Other owners</b>	<b>678,524,426</b>	<b>57.1%</b>
<b>Total as of March 31, 2026</b>	<b>1,187,498,248</b>	<b>100.0%</b>

## Financial Calendar

Interim Report Q1 2026, May 18, 2026

AGM 2026, June 17, 2026

Interim Report Q2, August 13, 2026

Interim Report Q3, November 5, 2026

Interim Report Q4, February 11, 2027

For more information, please contact

**Christian Lindholm**

CFO

Email: [christian.lindholm@acarix.com](mailto:christian.lindholm@acarix.com)

## Group - Consolidated Statement of Income

kSEK	Note	Jan-Mar 2026	Jan-Mar 2025	Year 2025
Revenue	7	2,424	1,729	7,361
Cost of goods sold		-456	-324	-1,123
<b>Gross profit</b>		<b>1,968</b>	<b>1,405</b>	<b>6,238</b>
Research and development costs		-2,682	-4,291	-14,755
Sales, general and administrative costs		-7,739	-11,146	-39,495
<b>Operating profit</b>		<b>-8,453</b>	<b>-14,032</b>	<b>-48,012</b>
Financial income		85	55	406
Financial costs		-413	-131	-485
<b>Profit before tax</b>		<b>-8,781</b>	<b>-14,108</b>	<b>-48,091</b>
Tax		-	-	-
<b>Net loss for the period</b>		<b>-8,781</b>	<b>-14,108</b>	<b>-48,091</b>
<b>Net income attributable to parent company's shareholders</b>		<b>-8,781</b>	<b>-14,108</b>	<b>-48,091</b>
Basic earnings per share (SEK) (1)		-0.01	-0.01	-0.04
Diluted earnings per share (SEK)		-0.01	-0.01	-0.04
Average number of shares, before dilution (thousands)		1,172,298	1,123,320	1,126,768
Average number of shares, after dilution (thousands)		1,172,298	1,123,320	1,126,768

1) EPS – Net profit for the period, attributable to shareholders of the Parent Company, divided by average number of shares outstanding.

## Group - Consolidated Statement of Comprehensive Income

kSEK	Note	Jan-Mar 2026	Jan-Mar 2025	Year 2025
Net loss for the period after tax		-8,781	-14,108	-48,091
<b>Items that may be reclassified to profit or loss</b>				
Foreign currency translation adjustment		563	-2,162	-2,774
<b>Other comprehensive income for the period, net of tax</b>		<b>563</b>	<b>-2,162</b>	<b>-50,865</b>
<b>Total comprehensive income for the period, net of tax</b>		<b>-8,218</b>	<b>-16,270</b>	<b>-50,865</b>
<b>Total comprehensive income attributable to:</b>				
Owners of Acarix		-8,218	-16,270	-50,865

## Group - Consolidated Statement of Financial Position

kSEK	Note	March 2026	March 2025	Year 2025
<b>Assets</b>				
<b>Tangible assets</b>				
Tangible assets		192	318	372
<b>Total tangible assets</b>		<b>192</b>	<b>318</b>	<b>372</b>
<b>Intangible assets</b>				
Acquired rights		3,072	3,324	3,119
Development projects, capitalized		2,783	5,132	3,356
<b>Total intangible assets</b>		<b>5,854</b>	<b>8,456</b>	<b>6,475</b>
<b>Current assets</b>				
Inventory		6,253	6,404	6,460
Accounts receivables		3,853	2,353	2,179
Other receivables		1,558	2,160	14,570
Cash and cash equivalents		25,793	45,048	18,274
<b>Total current assets</b>		<b>37,457</b>	<b>55,966</b>	<b>41,483</b>
<b>Total assets</b>		<b>43,503</b>	<b>64,739</b>	<b>48,330</b>
<b>Shareholders' equity and liabilities</b>				
<b>Equity</b>				
Share capital		11,875	11,233	11,647
Other contributed capital		691,926	675,272	686,269
Reserves		3,004	3,053	2,441
Retained earnings		-661,067	-615,541	-614,095
Result for the period		-8,781	-14,108	-48,091
<b>Total equity</b>		<b>36,956</b>	<b>59,909</b>	<b>38,171</b>
<b>Current liabilities</b>				
Accounts payable		1,306	1,260	3,108
Other liabilities		5,242	3,570	7,051
<b>Total current liabilities</b>		<b>6,548</b>	<b>4,830</b>	<b>10,159</b>
<b>Total equity and liabilities</b>		<b>43,503</b>	<b>64,739</b>	<b>48,330</b>

## Group - Consolidated Statement of Changes in Equity

kSEK	Share capital	Share premium	Other reserved	Retained earnings & result of the year	Total shareholders equity
<b>As at January 1, 2026</b>	<b>11,647</b>	<b>686,269</b>	<b>2,441</b>	<b>-662,186</b>	<b>38,171</b>
Profit/loss for the period				-8,781	-8,781
<b>Other comprehensive income:</b>					
Foreign exchange rate adjustment			563		563
<b>Total</b>	<b>11,647</b>	<b>686,269</b>	<b>3,004</b>	<b>-670,967</b>	<b>29,953</b>
<b>Transactions with owners:</b>					
Issue of warrants				1,119	1,119
Ongoing Share issue	228	6,271			6,499
Costs related to share issue		-614			-614
<b>At March 31, 2026</b>	<b>11,875</b>	<b>691,926</b>	<b>3,004</b>	<b>-669,848</b>	<b>36,956</b>

kSEK	Share capital	Share premium	Other reserved	Retained earnings & result of the year	Total shareholders equity
<b>As at January 1, 2025</b>	<b>11,233</b>	<b>675,272</b>	<b>5,215</b>	<b>-616,023</b>	<b>75,697</b>
Profit/loss for the period				-14,108	-14,108
<b>Other comprehensive income:</b>					
Foreign exchange rate adjustment			-2162		-2162
<b>Total</b>	<b>11,233</b>	<b>675,272</b>	<b>3,053</b>	<b>-630,131</b>	<b>59,427</b>
<b>Transactions with owners:</b>					
Issue of warrants				482	482
Share issue	3,861	86,951			90,812
Costs related to share issue		-3,832			-3,832
<b>At March 31, 2025</b>	<b>11,233</b>	<b>675,272</b>	<b>3,053</b>	<b>-629,649</b>	<b>59,909</b>

## Group - Consolidated Statement of Cash Flow

kSEK	Note	Jan - Mar 2026	Jan - Mar 2025	Year 2025
<b>Operating activities</b>				
Operating result		-8,451	-14,032	-48,012
Adjustment for depreciation		651	892	3,477
Financial items		-328	-77	-79
<b>Cash-flow before change of working capital</b>		<b>-8,128</b>	<b>-13,217</b>	<b>-44,613</b>
<b>Working capital adjustments:</b>				
Change in inventory		208	647	623
Change in receivables and prepayments		11,477	485	13,266
Change in trade and other payables		-2,444	418	-6,554
<b>Total change in working capital</b>		<b>9,241</b>	<b>1,550</b>	<b>7,335</b>
<b>Cash -flow from operating activities</b>		<b>1,113</b>	<b>-11,667</b>	<b>-37,278</b>
<b>Investing activities</b>				
Investment in fixed assets		180	-100	-757
<b>Cash-flow from investing activities</b>		<b>180</b>	<b>-100</b>	<b>-757</b>
<b>Financing activities</b>				
Rights issue after deduction of transaction costs		5,884	-	-
<b>Cash flow from financing activities</b>		<b>5,884</b>	<b>-</b>	<b>-</b>
<b>Cash flow for the period</b>		<b>7,177</b>	<b>-11,767</b>	<b>-38,035</b>
Currency translation differences		342	-1,800	-2,306
Cash and cash equivalents, beginning of period		18,274	58,615	58,615
<b>Cash and cash equivalents, end of period</b>		<b>25,793</b>	<b>45,048</b>	<b>18,274</b>

## Parent Company - Income Statement

kSEK	Note	Jan - Mar 2026	Jan - Mar 2026	Year 2025
<b>Other revenues</b>		<b>2,100</b>	<b>3,000</b>	<b>8,310</b>
Sales, general and administrative costs		-2,131	-2,083	-15,701
<b>Operating result</b>		<b>-31</b>	<b>917</b>	<b>-7,391</b>
Profit / Loss from shares in group companies		-6,024	-16,628	-33,776
Financial income		-	-	330
Financial expense		-391	-	-
<b>Profit before tax</b>		<b>-6,445</b>	<b>-15,712</b>	<b>-40,837</b>
Tax		-	-	-
<b>Net loss for the period</b>		<b>-6,445</b>	<b>-15,712</b>	<b>-40,837</b>
<b>Net income attributable to Parent Company's Shareholder</b>		<b>-6,445</b>	<b>-15,712</b>	<b>-40,837</b>

## Parent Company - Balance Sheet

kSEK	Note	March 2026	March 2025	Year 2025
<b>Assets</b>				
<b>Financial assets</b>				
Participations in subsidiaries		44,592	44,868	44,592
<b>Total financial assets</b>		<b>44,592</b>	<b>44,868</b>	<b>44,592</b>
<b>Current assets</b>				
Other receivables		830	3,813	12,630
Cash and cash equivalents		21,690	30,698	14,031
<b>Total current assets</b>		<b>22,520</b>	<b>34,511</b>	<b>26,661</b>
<b>Total assets</b>		<b>67,112</b>	<b>79,379</b>	<b>71,253</b>
<b>Shareholders' equity and liabilities</b>				
<b>Equity</b>				
Share capital		11,875	11,233	11,647
Other capital contribution		475,821	459,167	470,164
Retained earnings		-426,862	-395,292	-420,417
<b>Total equity</b>		<b>60,833</b>	<b>75,108</b>	<b>61,394</b>
<b>Current liabilities</b>				
Accounts payable		767	340	1,069
Intercompany payables		1,001	2,60	2,710
Other liabilities		4,512	1,250	6,080
<b>Total current liabilities</b>		<b>6,280</b>	<b>4,271</b>	<b>9,859</b>
<b>Total Equity and Liabilities</b>		<b>67,112</b>	<b>79,379</b>	<b>71,253</b>

## Parent Company - Consolidated Statement of Change in Equity

kSEK	Share capital	Share premium	Retained earnings & result of the year	Total shareholders equity
As at January 1, 2026	11,647	470,164	-420,417	61,394
<b>Profit/loss for the period</b>			<b>-6,445</b>	<b>-6,445</b>
<b>Total comprehensive income</b>	<b>11,647</b>	<b>470,164</b>	<b>-426,862</b>	<b>54,949</b>
<b>Transactions with owners:</b>				
Share issue				
Ongoing share issue	228	6,271		6,499
Costs related to share issue		-614		-614
<b>Total transactions with owners</b>	<b>228</b>	<b>5,657</b>		<b>5,885</b>
<b>At March 31, 2026</b>	<b>11,875</b>	<b>475,821</b>	<b>-426,862</b>	<b>60,833</b>

kSEK	Share capital	Share premium	Retained earnings & result of the year	Total shareholders equity
As at January 1, 2025	11,233	459,167	-379,580	90,820
<b>Profit/loss for the period</b>			<b>-15,712</b>	<b>-15,712</b>
<b>Total comprehensive income</b>	<b>11,233</b>	<b>459,167</b>	<b>-395,292</b>	<b>75,108</b>
<b>At March 31, 2025</b>	<b>11,233</b>	<b>459,167</b>	<b>-395,292</b>	<b>75,108</b>

## Notes

### Note 1 Corporate Information

#### Company Information

Acarix AB (559009-0667) is a limited liability company incorporated and domiciled in Malmö, Sweden. The registered office is located at Regus, Hyllie Boulevard 34, 215 32 Malmö, Sweden. Acarix's main activities are to develop, produce and market a new cardiovascular diagnostic method and similar equipment for the same and related services.

The Acarix Group Consists of:		
Acarix A/S	The main operating company	Incorporated and located in Denmark
Acarix GmbH	Supporting sales on the German market (under liquidation)	Incorporated and located in Germany, (under liquidation)
Acarix Inc	Supporting sales on the US market	Incorporated and located in USA
Acarix Ltd	Supporting sales on the UK market	Incorporated and located in UK

### Note 2 Basis of Preparation

The interim report for the Group and Parent Company comprises summary consolidated financial statements for Acarix AB (publ). The interim consolidated financial statements include the Company's wholly-owned subsidiaries according to above specification.

### Note 3 Accounting Policies

The consolidated report has been prepared in accordance with International Financial Reporting Standards (IFRS) and IAS 34, Interim Financial Reporting. Acarix continues to apply the same accounting principles and valuation methods as those described in the most recent annual report. The Parent Company report is prepared in accordance with RFR 2, Accounting for Legal Entities, the Swedish Annual Accounts Act and accounting principles and the valuation methods as those described in the most recent annual report.

### Note 4 Significant Accounting Policies, Judgments and Assumptions

In preparing the interim report, certain provisions under IFRS require management to make judgments, which may significantly impact the group's financial statements. For additional descriptions of significant judgments and estimates, refer to note 4 in the annual report 2025.

### Note 5 Risk Management

The Acarix Group is exposed to business and financial risks through its operations. These risks have been described at length in the company's annual report 2025. In addition to the risks described in these documents, no additional significant risks have been identified.

### Note 6 Related Parties

Related parties comprise the members of the Board of Directors and other senior executives. Apart from remuneration of the Board of Directors, a board member of the company has performed consulting services outside of their board

assignment in accordance with a signed consulting agreement, amounting to SEK 73,129. The transactions have been conducted on market terms..

## Note 7 Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the group and the revenue can be reliably measured, regardless of when the payment is received. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duty. The specific recognition criteria described below must also be met before revenue is recognized.

### Sale of goods

Revenue from the sale of goods is recognized when the significant control of ownership of the goods has passed to the buyer, usually on delivery of the goods. Revenue from the sale of goods is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates.

### Revenues from agreements with customers

Revenue 2026	Q1	Q2	Q3	Q4	2026
USA	2,010				2,010
Germany	339				339
Sweden	75				75
<b>Total</b>	<b>2,424</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2,424</b>

Revenue 2025	Q1	Q2	Q3	Q4	2025
USA	1,235	595	766	1,792	4,388
Germany	366	530	231	319	1,446
Sweden	128	16	-	30	174
Iraq	-	-	1,353	-	1,353
<b>Total</b>	<b>1,729</b>	<b>1,141</b>	<b>2,350</b>	<b>2,141</b>	<b>7,361</b>

## Affirmations

This interim report has been prepared in accordance with International Accounting Standard (IAS) 34 “Interim Financial Reporting” and in accordance with the Swedish Annual Accounts Act. With respect to the Parent Company, this interim report has been prepared in accordance with the Swedish Annual Accounts Act and in compliance with RFR2, Accounting for Legal Entities. The Board of Directors and the CEO certify that this interim report presents a true and fair overview of the Group’s and the Parent Company’s operations, financial position and results of operations, and describes the significant risks and uncertainties facing the Parent Company and the companies belonging to the group.

May 18, 2026

## Executive Management

### **Aamir Mahmood**

President & CEO

## Board of Directors

### **Jan Poulsen**

Chairman of the Board

### **Tony Das**

Board Member

### **Kenneth Nelson**

Board Member

### **Marlou Janssen-Counotte**

Board Member

## Leadership

**Aamir Mahmood**

President & CEO

**Christian Lindholm**

Chief Financial Officer

**Carma Connely**

Head of Operations & Customer Excellence

**Beji George**

Head of Global Strategy & Therapy Development

**Daniel Burke**

Head of Reimbursement & Market Access

**George Chrysant, MD**

Chief Medical Advisor



Hyllie Boulevard 34, 5TR

SE- 215 32 Malmö

[info@acarix.com](mailto:info@acarix.com)

[www.acarix.com](http://www.acarix.com)